scout

Case Based Peer Perspectives

bile duct cancer

City of Hope’s Dr Afsaneh Barzi reacts to how an elderly man with metastatic cholangiocarcinoma was treated through multiple lines of therapy and provides recommendations on the appropriate management of the disease in similar scenarios.

Tanios Bekaii-Saab, MD, FACP, presents a case study involving a 65-year-old patient diagnosed with stage 4 metastatic colorectal cancer and provides an in-depth discussion on the most effective therapy options for the disease.

Laurie Sehn, MD, presents the case of a 76-year-old man with relapsed diffuse B-cell lymphoma and highlights the treatment options available to patients.

An expert in hematology oncology, Jeff Sharman, MD, reviews the case of a 73-year-old woman with chronic lymphocytic leukemia (CLL) and shares key insights into factors to consider when selecting first- and second-line treatment.

Hossein Borghaei, DO

Thought leader in thoracic oncology, Hossein Borghaei, DO, reviews the case of a 59-year-old man with extensive-stage small-cell lung cancer and discusses the current treatment landscape by highlighting key clinical trial data on the safety and efficacy of lurbinectedin.

Jared Weiss, MD

Thought leader in thoracic oncology, Jared Weiss, MD, reviews the case of a 64-year-old woman with extensive-stage small-cell lung cancer and discusses the current treatment landscape by highlighting key clinical trial data on the safety and efficacy of lurbinectedin.

Chirag Shah, MD, MPH, an expert in gynecologic oncology, reviews the case of a 67-year-old woman with ovarian cancer and discusses factors to consider when selecting therapy including the recent results of the PRIMA and NOVA trials of niraparib in patients with ovarian cancer.

Rafael Fonseca, MD, discusses the case of a 77-year-old woman with multiple myeloma, treatment approach for patients with newly diagnosed multiple myeloma, and the trials providing insight into the treatment of this disease.

Erin Crane, MD, reviews the case of a 63-year-old woman with recurrent ovarian cancer and discusses treatment options, the Phase 3 NOVA trial, and the future of ovarian cancer treatment.